This was confirmed by a study by Winter et al., where they reported that germline TP53 mutations were associated with an increased incidence of secondary malignancies after hematopoietic stem cell transplantation (HSCT), highlighting the importance of germline testing in low-hypodiploid B-ALL to assess HSCT and possible benefits for patients with less genotoxic treatment strategies [124]. The gene discussed is TP53; the disease is acute lymphoblastic leukemia.